DOT1L expression is reduced in high-glucose conditions. Its overexpression protects against podocyte injury by upregulating PLCL1, which enhances fatty acid oxidation and reduces lipogenesis, mitigating podocyte damage in DKD. This evidence concerns the gene PLCL1 and diabetic kidney disease.